over? under?

Quote

Anonymous

Guest
I'm not a negative person, but rather I am professionally realistic. Projected GROWTH with Diovan and Avapro go generic?! These people have literally lost their minds. Cozzar pretty much kicked our asses, and that is a crap product.... Welchol and Sprix with another yet to be purchased product are our "saving graces" SERIOUSLY? So, I am taking an OVER/UNDER on when we think layoffs will actually happen. We all know these last layoffs weren't really "layoffs", but rather they were just a away to move DM's around, and clean house in some areas. I am talking like a serious sales force reduction 25-40%...anyone? I am thinking December. I'll take the under for December....
 






The price of Oil has a bigger effect on our future layoffs, gas costs were $2 six months ago, $4+ per gallon now. I agree with your 25% for market forces downsizing, then up the ante another 25% for the added costs for hauling our deadend jobs around town. Thats only if Oil stays at $4, if it hits $5 this summer, we could see more than 50% cut AND before december. My guess is we increase selling more pixie dust for loose stools, this would save the day. Just sayin...
 






I pick Over, I think we will have "Layoffs" late 2012, Diovan goes Generic in 2012. I think this "CEM" is just the platform to start the layoffs. Never in my sales career have I had a company give a sales projection of a lost in revenue "Benicar" but our managers still want us to have growth in Benicar ???????

My saying has always been if we can't beat Diovan when it's branded and tier III how are we going to beat them when it goes generic.

Generic Cozaar has kicked out ass big time, time will tell how bad are market share will maybe lower than Tevetan! LOL
 






If you seriously aren't looking for another career I strongly suggest that you start tomorrow. It is not "if" but "when" the layoffs occur do you want to hit the pavement with all the others? DSI pays so low that you probably won't take a hit and trust me there are other careers out there that can be much more rewarding than pharma. They were great jobs but generic Diovan is going to be tuff to overcome...say that out loud a few times and you will slowly realize what a daunting task it will be to overcome obstacle. There is life outside of pharma, trust me....and it's pretty darn good...
 






You chose to join this company knowing what products it has. You can take the paycheck and complain about the "doggie" products at the same time. Other reps have to sell ancient off-patent products as their only products. Consider yourself lucky.
 






says it all. Game over!

"Pfizer Inc. and rival U.S. drugmakers are poised to report the industry’s biggest drop in quarterly profit in more than four years as the companies cope with record patent losses in 2011.

Earnings at the 11 drugmakers listed in the Standard & Poor’s 500 Index probably fell 1.4 percent in the first quarter, even as overall profits for companies in the index may have gained 12 percent, according to analyst estimates compiled by Bloomberg. Pharmaceutical profits last fell in 2009’s first quarter, and the current drop is the biggest since a 3.5 percent slip in the final quarter of 2006.

Pfizer, Merck & Co. and Bristol Myers Squibb Co. are eliminating jobs, cutting costs and shedding business units to prepare for patent expirations. In 2011, drugmakers face generic rivals to products with $34 billion in yearly sales, a figure 34 percent higher than last year. Sales at risk from patent losses will swell to $147 billion by 2015.

“A brand can lose 40 percent of sales and 50 percent of volume globally in the first two years after generic entry,” said Chris Bowe, a New York-based analyst for Informa Plc, a London industry research firm, “It’s now not uncommon to see a brand lose 50 percent of U.S. sales in two quarters.”

Four U.S. drugmakers report earnings next week. Eli Lilly & Co., based in Indianapolis, will report on April 18, followed by New Brunswick, N.J.-based Johnson & Johnson and New York-based Forest Laboratories Inc. on April 19 and Abbott Laboratories, of Abbott Park, Ill., on April 20. The average quarterly earnings growth for drugmakers was 10 percent since the first quarter of 2007.

Drug profits last quarter were also hampered by the U.S. health-care overhaul, which mandates product discounts for older Americans, as well as price cuts from European drugmakers.

To make up for lost sales, Chief Executive Ian Read at New York-based Pfizer said last quarter he was reviewing possible divestiture of each company division — baby formula, animal health, consumer and established products — to concentrate on drug development. On April 4, Pfizer agreed to sell Capsugel, its smallest unit, which manufactures pill casings, to KKR & Co. for $2.38 billion.

“Everybody knows it’s coming, everyone’s placed their bets,” said Les Funtleyder, a New York-based fund manager at Miller Tabak & Co. “What pharma investors are interested in is pipelines and corporate transactions — either acquisitions or divestitures. That’s going to dominate the discussions.”
 
























Top Bottom
Back
Quote